The world stands on the edge of an era when gene editing can address many serious ills plaguing humankind, according to Jennifer Doudna, whose work on the gene editing technique known as CRISPR-Cas9 earned her the 2020 Nobel Prize in chemistry.
But first, she said, there is a problem to solve: ensuring that as these technologies become approved to treat and even cure certain human diseases, they reach everyone who needs them.
In a pair of talks delivered last week at Harvard Medical School, Doudna delved into her laboratory’s latest endeavors to understand and improve CRISPR-based gene editing techniques so they can become cheaper to manufacture, easier to deliver into the body, and more effective at lower doses.
